Antibe Therapeutics Inc.
TSX:ATE.TO
0.29 (CAD) • At close April 8, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Antibe Therapeutics Inc. |
Symbool | ATE.TO |
Munteenheid | CAD |
Prijs | 0.295 |
Beurswaarde | 15,637,773 |
Dividendpercentage | 0% |
52-weken bereik | 0.15 - 1.23 |
Industrie | Medical Devices |
Sector | Healthcare |
CEO | Mr. Daniel Marcel Legault J.D., L.L.B. |
Website | https://www.antibethera.com |
An error occurred while fetching data.
Over Antibe Therapeutics Inc.
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (CAD)
Cijfers zijn in miljoenen (CAD)